Merck Offers Promising Results; a Must Have Dividend Stock

Published October 15, 2012

Merck Offers Promising Results; A Must Have Dividend Stock

Filed under: drug treatment news articles

MRK's only patent expiration to speak of is Singulair's, the drug which lost its marketing exclusivity in August in the U.S. to be followed by major European markets in early 2013 and in Japan by 2016. The drug, used for the prevention and long-term …
Read more on Seeking Alpha

Front-Line TKI Therapy for Chronic-Phase CML: the Luxury of Choice

Filed under: drug treatment news articles

The modern era of targeted tyrosine kinase inhibitor (TKI) therapy for the treatment of human malignancies was ushered in by the BCR-ABL TKI imatinib(Drug information on imatinib) (Gleevec) in glorious fashion by Brian Druker and colleagues.[1] Upon …
Read more on Cancer Network